In an exciting development that could reshape the therapeutic landscape for head and neck squamous cell carcinoma (HNSCC), researchers have uncovered a novel approach that effectively suppresses the tumor’s metabolic machinery while inducing a unique form of cell death. The study centers on the targeting of the USP10/SCD1 axis, a critical regulator of lipogenesis, using RAF265, a small molecule inhibitor previously known for its anti-cancer properties. This dual-action strategy not only attenuates lipid synthesis but also triggers ferroptosis, a non-apoptotic cell death pathway, thus offering a promising new avenue for combating this aggressive malignancy.
Lipogenesis, the metabolic process responsible for synthesizing fatty acids and lipids essential for membrane biogenesis and signaling, is often upregulated in cancers to meet the demands of rapid cellular proliferation and survival. The enzyme stearoyl-CoA desaturase-1 (SCD1) plays a pivotal role in this process by converting saturated fatty acids into monounsaturated fatty acids, which are critical components of cellular membranes and energy storage molecules. Elevated SCD1 activity has been implicated in the progression and chemoresistance of various tumors, including HNSCC, making it a prime target for therapeutic intervention.
USP10, a ubiquitin-specific protease, emerges as an upstream regulator of SCD1, influencing its stability and activity through deubiquitination. The interplay between USP10 and SCD1 thus forms a crucial axis that sustains lipogenesis within cancer cells. By focusing on this axis, the researchers have identified a key vulnerability in HNSCC’s metabolic framework. RAF265, initially characterized as a multikinase inhibitor, demonstrates an unexpected potency in disrupting this axis, thereby suppressing lipid synthesis critical for tumor maintenance and growth.
Mechanistically, RAF265 engages with USP10, diminishing its ability to stabilize SCD1. This decreased stabilization triggers the degradation of SCD1, leading to a marked reduction in lipid desaturation activity. Reduced levels of monounsaturated fatty acids result in impaired membrane synthesis and altered lipid signaling, which compromises the proliferative capacity of cancer cells. This lipid metabolic blockade thus acts as a metabolic bottleneck, effectively starving cancer cells of essential components for survival.
Beyond metabolic suppression, an intriguing consequence of this disruption is the induction of ferroptosis — an iron-dependent, lipid peroxidation-driven form of regulated cell death distinct from apoptosis or necrosis. Ferroptosis is characterized by the accumulation of lethal lipid reactive oxygen species (ROS), which damage cellular membranes and trigger cell demise. The depletion of monounsaturated fatty acids due to SCD1 inhibition exacerbates membrane vulnerability to peroxidation, effectively priming cells for ferroptotic death.
Ferroptosis induction holds significant therapeutic promise due to its potential to overcome apoptosis resistance, a common hurdle in cancer treatment. By leveraging the USP10/SCD1 axis, RAF265 not only dovetails metabolic inhibition with ferroptosis, enhancing the cytotoxic impact, but also circumvents traditional resistance mechanisms frequently employed by tumor cells. This dual mechanism amplifies the therapeutic efficacy in head and neck cancers, which remain notoriously challenging to treat.
The researchers employed comprehensive molecular analyses, including gene knockdown and overexpression experiments, to delineate the roles of USP10 and SCD1. These approaches validated that manipulating USP10 levels directly influences SCD1 protein stability and lipid desaturation activity. In addition, pharmacological inhibition using RAF265 mirrored these genetic modulations, consolidating the compound’s ability to target this regulatory axis effectively.
In vitro studies showed that RAF265 treatment led to significant reductions in lipid droplet accumulation within HNSCC cells, highlighting the suppression of lipogenesis. Correspondingly, markers of ferroptosis, such as increased lipid peroxidation and iron accumulation, were elevated, confirming the induction of this cell death pathway. Notably, the combination of RAF265 with ferroptosis inhibitors reversed these effects, underscoring the specificity of the induced ferroptotic mechanism.
In vivo experiments using xenograft models demonstrated that systemic RAF265 administration significantly slowed tumor growth without evident systemic toxicity. Tumor tissues harvested from treated animals exhibited decreased SCD1 expression, diminished lipid content, and heightened ferroptosis-associated damage. These findings reinforce the translational relevance of targeting the USP10/SCD1 axis in a solid tumor context.
An additional layer of analysis revealed that RAF265 treatment modulated key ferroptosis regulators, including glutathione peroxidase 4 (GPX4), further sensitizing cancer cells to oxidative lipid damage. The downregulation of GPX4 upon RAF265 exposure increases susceptibility to ferroptosis, which synergizes with SCD1 suppression to amplify cell death. This multifaceted targeting underscores the therapeutic depth achievable by manipulating the USP10/SCD1 axis.
The implications of this study extend beyond HNSCC, as aberrant lipid metabolism and ferroptosis resistance contribute to the pathophysiology of various cancers. Targeting deubiquitinases such as USP10 offers an innovative strategy for modulating metabolic enzymes post-translationally, presenting a versatile approach to cancer treatment. RAF265’s activity against this axis showcases the therapeutic potential of repurposing kinase inhibitors to engage novel molecular targets within the tumor microenvironment.
Future research directions highlighted by the team include the exploration of combination regimens wherein RAF265 is paired with existing chemotherapeutics or immune checkpoint inhibitors to exploit potential synergistic effects. Moreover, the identification of biomarkers predictive of response to USP10/SCD1 axis inhibition will be critical in personalizing treatment and enhancing clinical outcomes.
This breakthrough underscores the expanding recognition of metabolic vulnerabilities in oncology and the emergence of ferroptosis as a powerful modality for cancer eradication. By precisely targeting the USP10/SCD1-driven metabolic network, RAF265 not only suppresses oncogenic lipogenesis but also orchestrates an effective ferroptotic assault on malignant cells, propelling new hope for patients afflicted with head and neck squamous cell carcinoma.
As cancer therapy continues to evolve with an emphasis on precision medicine, interventions such as these pave the way for more refined and robust approaches that dismantle tumor resilience at multiple molecular fronts. The detailed mechanistic insights and compelling preclinical results conveyed in this report signal a promising horizon where metabolic modulation and ferroptosis activation become mainstays in cancer treatment paradigms.
This landmark study, recently published, invites the scientific and medical communities to reimagine therapeutic strategies that transcend traditional apoptosis induction models and embrace the complexity of cancer metabolism and cell death regulation. The targeting of the USP10/SCD1 axis by RAF265 is poised to become a cornerstone in the emerging armamentarium against head and neck squamous cell carcinoma and potentially other malignancies fueled by aberrant lipid metabolism.
Subject of Research: Targeting the USP10/SCD1 axis to suppress lipogenesis and induce ferroptosis in head and neck squamous cell carcinoma.
Article Title: Targeting USP10/SCD1 axis by RAF265 suppresses lipogenesis and induced ferroptosis in head and neck squamous cell carcinoma.
Article References:
Shi, S., Sun, X., Kui, X. et al. Targeting USP10/SCD1 axis by RAF265 suppresses lipogenesis and induced ferroptosis in head and neck squamous cell carcinoma. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03180-1
Image Credits: AI Generated
